Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

Craig Mello, PhD, 2006 Nobel Prize in Physiology or Medicine Laureate, the Blais University Chair in Molecular Medicine and distinguished Professor of RNA therapeutics at UMass Chan Medical School, said:"It is exciting to see siRNA from our unique platform at the RNA Therapeutic Institute at UMass Chan Medical School, being deployed to yet another new organ system. Thanks to the unique accessibility of skin, we believe siRNA can result in a step change innovation in dermatological indications." ...

Canada, 27/03/2025 (informazione.news - comunicati stampa - salute e benessere)

 

: " "

 

The Phase IIa trial will investigate if ALY-101 is safe and well tolerated following injections in the scalp in subjects with alopecia areata randomly vs. placebo every 4 weeks for a treatment period of 8 weeks. The study is expected to be completed in 2026. More information on the clinical study can be found on Clinicaltrials.gov: NCT06826196. The Company previously announced the clearance of its CTA/IND for ALY-101 and remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027.

Alys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich ), Craig Mello (UMass Chan Medical School), Eric Deutsch ( Gustave Roussy ) and Mark Prausnitz ( Georgia Institute of Technology ). Alys is led by dermatology specialist, co-founder and COO Thibaud Portal . 

It was formed from the aggregation of 6 asset-centric Medicxi companies – Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis. The Company is entering the clinic with the siRNA platform developed by Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape. In addition, Alys is advancing its mastocyte-selective therapies developed by Granular Therapeutics, with CTA/IND expected in 2025.
For further information, please visit www.alyspharma.com.

View original content:https://www.prnewswire.co.uk/news-releases/alys-pharmaceuticals-announces-dosing-of-first-patient-in-phase-iia-trial-of-aly-101-for-alopecia-areata-302412448.html